Potential role for somatostatin analogues in breast cancer: Rationale and description of an ongoing trial

Pollak, Michaël; Gallant, Karen R.; Poisson, Roger; Harris, Alan G.

doi:10.1016/0026-0495(92)90045-c

Cited by 5 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…M RA results in growth stimulation or no change in cell growth, while 2 M RA causes growth inhibition. The modulation of RA effects by the IGF-I receptor suggests that substances that lower serum IGF-I levels such as the anti-estrogen, tamoxifen (Lonning et al, 1992), or inhibitors of IGF action including somatostatin analogues (Pollak et al, 1989(Pollak et al, , 1992, might augment the ability of RA to inhibit breast cancer growth in vivo. This finding provides an additional rationale for the clinical combination of these agents in the treatment of breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells

Bentel

Lebwohl

Cullen

et al. 1995

Journal Cellular Physiology

View full text Add to dashboard Cite

Retinoids are currently being tested for the treatment and prevention of several human cancers, including breast cancer. However, the anti-cancer and growth inhibitory mechanisms of retinoids are not well understood. All-trans retinoic acid (RA) inhibits the growth of the estrogen receptor-positive (ER+) breast cancer cell line, MCF-7, in a reversible and dose-dependent manner. In contrast, insulin-like growth factors (IGF-I, IGF-II) and insulin are potent stimulators of the proliferation of MCF-7 and several other breast cancer cell lines. Pharmacologic doses of RA (> or = 10(-6) M) completely inhibit IGF-I-stimulated MCF-7 cell growth. Published data suggest that the growth inhibitory action of RA on IGF-stimulated cell growth is linear and dose-dependent, similar to RA inhibition of unstimulated or estradiol-stimulated MCF-7 cell growth. Surprisingly, we have found that IGF-I or insulin-stimulated cell growth is increased to a maximum of 132% and 127%, respectively, by cotreatment with 10(-7) M RA, and that 10(-9) - 10(-7) M RA increase cell proliferation compared to IGF-I or insulin alone. MCF-7 cells that stably overexpress IGF-II are also resistant to the growth inhibitory effects of 10(-9) - 10(-7) M RA. Treatment with the IGF-I receptor blocking antibody, alpha IR-3, restores RA-induced growth inhibition of IGF-I-treated or IGF-II-overexpressing MCF-7 cells, indicating that the IGF-I receptor is mediating these effects. IGFs cannot reverse all RA effects since the altered cell culture morphology of RA-treated cells is similar in growth-inhibited cultures and in IGF-II expressing clones that are resistant to RA-induced growth inhibition. These results indicate that RA action on MCF-7 cells is biphasic in the presence of IGF-I or insulin with 10(-9) - 10(-7) M RA enhancing cell proliferation and > or = 10(-6) M RA causing growth inhibition. As IGF-I and IGF-II ligands are frequently detectable in breast tumor tissues, their potential for modulation of RA effects should be considered when evaluating retinoids for use in in vivo experimental studies and for clinical purposes. Additionally, the therapeutic use of inhibitors of IGF action in combination with RA is suggested by these studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells

Bentel

Lebwohl

Cullen

et al. 1995

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…51 The efficacy of α particle-emitting 211 At-labeled trastuzumab in a rat model of breast carcinomatous meningitis was demonstrated preclinically. 52 In addition, 68 Ga-HER2-nanobody PET/CT has been successfully tested as a safe procedure, with tolerability, favorable biodistribution, and high uptake in HER2-positive lesions of breast carcinoma compared with normal peripheral tissues. Phase 2 clinical trial of the 68 Ga-DOTA-anti-HER2 VHH1 for PET/CT imaging of breast cancer brain metastases is ongoing.…”

Section: Figurementioning

confidence: 99%

“…52 In addition, 68 Ga-HER2-nanobody PET/CT has been successfully tested as a safe procedure, with tolerability, favorable biodistribution, and high uptake in HER2-positive lesions of breast carcinoma compared with normal peripheral tissues. Phase 2 clinical trial of the 68 Ga-DOTA-anti-HER2 VHH1 for PET/CT imaging of breast cancer brain metastases is ongoing. If successful, it might warrant the development of therapeutic analogs of this radiotracer for targeted radionuclide therapy as theranostic strategy.…”

Section: Figurementioning

confidence: 99%

“…66,67 The SSTR-mediated therapeutic effect on breast cancer was attributed to inhibition of cell proliferation and induction of apoptosis (so-called direct mechanism). 68,69 Somatostatin receptor autoradiography using 125 I-[tyr3]-SMS201-995 revealed receptor-specific uptake in 342 breast tumor samples including both primary tumors and distant metastases with positive SSTR. 70 In in vivo PET visualization using 68 Ga-labeled agonist ( 68 Ga-DOTATOC and 68 Ga-DOTATATE) and antagonist ( 68 Ga-NODAGA-JR11), somatostatin analogs were studied in mice bearing breast cancer xenografts expressing SSTR type 2 (ZR-75-1 cell culture).…”

Section: Somatostatin Receptorsmentioning

confidence: 99%

“…1). PET and SPECT molecular imaging agents comprise radionuclides emitting, respectively, positrons (eg, 68 Ga [t ½ = 68 minutes]) and γ-ray photons (eg, 99m Tc [t ½ = 6 hours]; 123 I [t ½ = 13.3 hours]). 17 Radiotherapeutical agents rely on αand β − -emitting radionuclides.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Theranostic Approach in Breast Cancer

et al. 2021

View full text Add to dashboard Cite

Breast cancer is the most frequent invasive malignancy and the second major cause of cancer death in female subjects mostly due to the considerable diagnostic delay and failure of therapeutic strategies. Thus, early diagnosis and possibility to monitor response to the treatment are of utmost importance. Identification of valid biomarkers, in particular new molecular therapeutic targets, that would allow screening, early patient identification, prediction of disease aggressiveness, and monitoring response to the therapeutic regimen has been in the focus of breast cancer research during recent decades. One of the intensively developing fields is nuclear medicine combining molecular diagnostic imaging and subsequent (radio)therapy in the light of theranostics. This review aimed to survey the current status of preclinical and clinical research using theranostic approach in breast cancer patients with potential to translate into conventional treatment strategies alone or in combination with other common treatments, especially in aggressive and resistant types of breast cancer. In addition, we present 5 patients with breast cancer who were refractory or relapsed after conventional therapy while presumably responded to the molecular radiotherapy with 177Lu-trastuzumab (Herceptin), 177Lu-DOTATATE, and 177Lu-FAPI-46.

show abstract

The diagnostic utility of somatostatin receptor scintigraphy in oncology

Valkema¹,

Steens²,

Cleton

et al. 1996

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Somatostatin receptor scintigraphy (SRS) with the diethylenetriaminopentaacetic-acid-conjugated somatostatin analogue [111In-DTPA-D-Phe1] octreotide, also known as 111In-pentetreotide, is a new non-invasive modality for the evaluation of tumours that express receptors for somatostatin. These receptors are present on neuroendocrine and other tumours, including lymphomas and some breast cancers. In oncology SRS is a promising diagnostic tool for localizing primary tumours, staging, control and follow-up after therapy, and for identification of patients who may benefit from therapy with unlabelled octreotide or, in the future, with radiolabelled octreotide. In the past few years many small and large studies investigating various aspects of SRS have been reported. In this review the value of SRS in the management of individual tumour types is explored. For many tumours the best sensitivity in lesion detection is only achieved by very careful imaging after the administration of at least 200 MBq 111In-pentetreotide. On the basis of the current experience the main value of SRS in oncology is in the staging and evaluation of gastroenteropancreatic tumours, paragangliomas, small-cell lung cancer and lymphomas. Promising areas for SRS are the evaluation of breast cancer, non-medullary thyroid cancer and melanoma, and initial results with targeted radionuclide therapy using radiolabelled octreotide have been reported.

show abstract

Potential role for somatostatin analogues in breast cancer: Rationale and description of an ongoing trial

Cited by 5 publications

References 16 publications

Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells

Insulin‐like growth factors modulate the growth inhibitory effects of retinoic acid on MCF‐7 breast cancer cells

Theranostic Approach in Breast Cancer

The diagnostic utility of somatostatin receptor scintigraphy in oncology

Contact Info

Product

Resources

About